Diabetes has become the main cause of endstage renal disease. The costs for the treatment of diabetic patients with endstage renal disease • Which is an appropriate time to determine the albuminuria for the purpose of precaution and course-control of the diabetic nephropathy? a) in type 1 diabetic patients b) in type 2 diabetic patients • Which method of testing is most effective concerning economic and medical aspects?
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• Which is an appropriate time to determine the albuminuria for the purpose of precaution and course-control of the diabetic nephropathy? a) in type 1 diabetic patients b) in type 2 diabetic patients • Which method of testing is most effective concerning economic and medical aspects?
Methods
Published literature from 1998 up to 2004 was identified by searching in the most important databases. Most of the guidelines were found by hand searching in the internet.
Results
Of 2,792 citation titles and abstracts examined, 274 articles were retrieved for full-text review. Five metaanalyses and reviews, one review about clearing of guidelines (regarding 18 international guidelines) and four guidelines met the inclusion criteria for screening for microalbuminuria and type 1 diabetes. Seven metaanalyses, one HTA report, one review about clearing of guidelines (regarding 17 international guidelines), and seven guidelines met the inclusion criteria for screening for microalbuminuria and type 2 diabetes. At the moment, the determination of albuminuria still has a great significance because it is recommended in most published literature and guidelines. The time to determine the albuminuria depends on the age of the patients and their type of diabetes. Type 2 diabetic patients should start the determination when the diabetes is diagnosed whereas the deter-mination is recommended five years later when type 1 diabetic patients are concerned. Most guidelines recommend a screening for microalbuminuria every year.
Discussion and conclusion
All guidelines and most of the literature recommend this screening. However, these recommendations are only based on expert consensus. The specificity of this screening is rather low. False positive tests in type 2 diabetic patients will cause psychological problems.
A positive test leads to the recommendation to achieve "normal blood pressure" and "normoglycaemia" -but this applies to each diabetic patient. Based on these facts, the screening for albuminuria in type 1 or type 2 diabetes patients cannot be recommended as long as benefit has not been demonstrated by large, clinical, controlled trials. Without an evidence of the benefit, this screening cannot be economic. 
Results and discussion
Of 2,792 citation titles and abstracts examined, 274 articles were retrieved for full-text review. Five metaanalyses and reviews, one review about clearing of guidelines (regarding 18 international guidelines) and four guidelines met the inclusion criteria for screening for microalbuminuria and type 1 diabetes. Seven metaanalyses, one HTA report, one review about clearing of guidelines (regarding 17 international guidelines), and seven guidelines met the inclusion criteria for screening for microalbuminuria and type 2 diabetes.
The methodological quality of the articles varied but was on average level. Most of these trials were cross-sectional and cohort studies. Almost each guideline recommends a screening for microalbuminuria every year. Type 1 diabetic patients should start the screening five years after diagnosis of diabetes. Different recommendations exist with regard to the screening for microalbuminuria in young type 1 diabetic patients, especially in puberty. Microalbuminuric type 1 and type 2 patients should be screened every three to six months. Most of these recommendations are only based on expert consensus. There are no randomised controlled trials which proof the recommendations. Sensitivity and specificity of microalbuminuria are high in type 1 diabetes, whereas in type 2 diabetes sensitivity of the microalbuminuria is high but specificity is only moderate. As the test will be incorrectly positive in many type 2 diabetic patients, these patients suffer the threatening of dialysis. In addition, there is no real consequence of a positive test result regarding the therapy of the diabetic nephropathy. The only proofed therapy is to achieve strictly normal values of glycosylated hemoglobin (HbA1c) and a normal blood pressure (<120/80 mm Hg).
Conclusion
Most guidelines recommend an albumin screening every year, but these recommendations are only based on expert consensus. The specificity of this screening is rather low. False positive tests in type 2 diabetic patients cause psychological problems. The consequence of a positive test leads to the recommendation to achieve a "normal blood pressure" and a "normoglycaemia" -but this applies to each diabetic patient. Based on these facts, the screening for albuminuria in type 1 or type 2 diabetes patients cannot be recommended. Without the evidence of the benefit, this screening cannot be economic. In order to prove a benefit of this screening, large, clinical, controlled trials are necessary.
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